Advances in the Clinical Application of Novel PCSK9 Inhibitors for High-Risk Atherosclerotic Cardiovascular Disease
DOI:
https://doi.org/10.54097/wp0rhk16Keywords:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; Low-density lipoprotein cholesterol (LDL-C); Atherosclerosis; Lipid-lowering therapy; Cardiovascular risk reduction.Abstract
Dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD), the leading cause of morbidity and mortality worldwide. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes hepatic low-density lipoprotein receptor (LDLR) degradation, elevating plasma low-density lipoprotein cholesterol (LDL-C) and contributing to plaque initiation, progression, and destabilization via lipid-dependent and -independent pathways (e.g., inflammation, endothelial dysfunction, thrombosis). PCSK9 inhibition is a validated target for intensive lipid management Beyond statins, monoclonal antibodies (evolocumab, alirocumab) and siRNA-based therapy (inclisiran) achieve reductions in LDL-C of >50%. Large outcome trials (FOURIER, ODYSSEY OUTCOMES, ORION series) have demonstrated reduced major adverse cardiovascular events (MACE) and favorable safety in high-risk populations including acute coronary syndrome, familial hypercholesterolemia, and statin intolerance. Newer approaches include oral small molecule inhibitors (e.g., MK-0616, AZD0780), therapeutic vaccines (e.g., AT04A), and gene-editing (e.g., VERVE-101) with improved adherence, durability or potential cure. For patients with very-high-risk or high-risk ASCVD who do not achieve LDL-C targets with traditional therapies, clinical guidelines, including China-specific recommendations, support the use of PCSK9 inhibitors to lower LDL-C and further reduce CV risk.
Downloads
References
[1] Wang ZW, et al. Chinese Guidelines for the Management of Blood Lipids (2023). Chinese Circulation Journal. 2023;38(3):237-271.
[2] Banach, M., et al., Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf, 2015. 14(6): p. 935–55.
[3] Guan, Y., et al., PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling. Circulation, 2025. 151(21): p. 1512–1526.
[4] Wang, Y., et al., Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res, 2012. 53(9): p. 1932–43.
[5] Lin, Z., et al., PCSK9 E670G polymorphism increases risk of coronary artery disease in a Chinese Han population. J Int Med Res, 2024. 52(10): p. 300060519892177.
[6] Cohen, J.C., et al., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006. 354(12): p. 1264–72.
[7] Giunzioni, I., et al., Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol, 2016. 238(1): p. 52–62.
[8] Ferri, N., et al., Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012. 220(2): p. 381–6.
[9] Ding, Z., et al., Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal, 2015. 22(9): p. 760–71.
[10] Tang, Z.H., et al., new role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway. Atherosclerosis, 2017. 262: p. 113–122.
[11] Ragusa, R., et al., PCSK9 and coronary atherosclerosis progression beyond LDL-cholesterol in coronary artery disease patients. Eur J Clin Invest, 2025. 55(11): p. e70083.
[12] Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation, 2021. 143(1): p. e4.
[13] Paciullo, F., et al., Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression. Thromb Res, 2022. 213: p. 170–172.
[14] Schwartz, G.G., et al., Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018. 379(22): p. 2097–2107.
[15] Zahger, D., et al., Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome. J Am Coll Cardiol, 2024. 84(11): p. 994–1006.
[16] White, H.D., et al., Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J, 2022. 43(16): p. 1554–1565.
[17] Raber, L., et al., Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA, 2022. 327(18): p. 1771–1781.
[18] Blom, D.J., et al., Efficacy and Safety of Alirocumab in Adults with Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. J Am Coll Cardiol, 2020. 76(2): p. 131–142.
[19] Catapano, A.L., et al., 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed), 2017. 70(2): p. 115.
[20] Hadjiphilippou, S. and K.K. Ray, Evolocumab and clinical outcomes in patients with cardiovascular disease. J R Coll Physicians Edinb, 2017. 47(2): p. 153–155.
[21] O'Donoghue, M.L., et al., Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 2022. 146(15): p. 1109–1119.
[22] Hochholzer, W. and F.J. Neumann, [The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. Dtsch Med Wochenschr, 2016. 141(11): p. 782–5.
[23] Cholesterol Treatment Trialists, C., et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010. 376(9753): p. 1670–81.
[24] Koskinas, K.C., et al., Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol, 2019. 74(20): p. 2452–2462.
[25] Lancellotti, P. and C. Oury, A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med, 2017. 376(18): p. e38.
[26] 26. Ray, K.K., et al., Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med, 2017. 376(15): p. 1430–1440.
[27] Nishikido, T. and K.K. Ray, Inclisiran for the treatment of dyslipidemia. Expert Opin Investig Drugs, 2018. 27(3): p. 287–294.
[28] Wright, R.S., et al., Effects of Inclisiran in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials. Mayo Clin Proc, 2024.
[29] Raal, F.J., et al., Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med, 2020. 382(16): p. 1520–1530.
[30] Ray, K.K., et al., Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol, 2023. 11(2): p. 109–119.
[31] Leiter, L.A., et al., Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab, 2024. 26(8): p. 3223–3237.
[32] Johns, D.G., et al., Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low-Density Lipoprotein Receptor. Circulation, 2023. 148(2): p. 144–158.
[33] Ballantyne, C.M., et al., Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol, 2023. 81(16): p. 1553–1564.
[34] Ballantyne, C.M., et al., Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults with Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA, 2026. 335(2): p. 129–139.
[35] Koren, M.J., et al., An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol, 2025. 85(21): p. 1996–2007.
[36] Toth, S., D. Pella, and J. Fedacko, Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia. Cardiol Ther, 2020. 9(2): p. 323–332.
[37] Landlinger, C., et al., The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J, 2017. 38(32): p. 2499–2507.
[38] Galabova, G., et al., Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One, 2014. 9(12): p. e114469.
[39] Momtazi-Borojeni, A.A., et al., Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis, 2019. 283: p. 69–78.
[40] Zeitlinger, M., et al., A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol, 2021. 77(10): p. 1473–1484.
[41] Ding, Q., et al., Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res, 2014. 115(5): p. 488–92.
[42] Hooper, A.J., X.L. Tang, and J.R. Burnett, VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert Opin Investig Drugs, 2024. 33(8): p. 753–756.
[43] Vafai, S., et al., abstract 4139206: Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol. Circulation, 2024. 150(Suppl_1): p. A4139206–A4139206.
[44] Lee, R.G., et al., Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation, 2023. 147(3): p. 242–253.
[45] Zhou Y. Expert consensus on medication therapy management pathway for patients with coronary atherosclerotic heart disease[J]. Journal of Clinical Medication Therapy, 2023, 21(06): 1 18.
[46] Wang Z W, Guo Y L. Chinese guidelines for lipid management (primary care version, 2024)[J]. Chinese Circulation Journal, 2024, 39(04): 313 321.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
